MK-677 vs CJC-1295 + Ipamorelin
MK-677 and the CJC-1295 + ipamorelin stack are the two most popular approaches to growth hormone optimization — but they differ fundamentally in administration (oral vs injectable), mechanism, selectivity, and side effect profile. This comparison helps clarify which approach might be more appropriate for different goals.
MK-677
An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
| Category | MK-677 | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Administration | Oral (capsule/liquid) — daily | Subcutaneous injection — daily or several times per week | Subcutaneous injection — daily |
| Mechanism | Non-peptide ghrelin receptor agonist (GHS-R1a) | GHRH receptor agonist (extends natural GHRH signal) | Selective ghrelin receptor agonist (GHS-R1a) |
| GH Release Pattern | Sustained elevation over 24 hours (less pulsatile) | Amplifies natural GH pulse amplitude | Triggers discrete GH pulses |
| Appetite Effects | Significant appetite increase (common complaint) | No significant appetite change | Minimal appetite change (highly selective) |
| Cortisol Effects | May increase cortisol modestly | No significant cortisol change | No cortisol or prolactin increase |
| Insulin Sensitivity | May worsen insulin sensitivity with prolonged use | Neutral to minimal impact | Neutral |
| Evidence Level | Moderate — multiple human trials, not FDA-approved | Moderate — Phase I/II human data | Moderate — human pharmacodynamic studies |
| Convenience | High — simple daily oral dose | Lower — requires injection | Lower — requires injection |
| Cost (Compounded) | ~$50–100/month | ~$100–200/month | ~$80–150/month |
Summary
The choice between oral MK-677 and injectable CJC-1295 + ipamorelin comes down to convenience vs selectivity. MK-677's oral route is its biggest advantage — no injections, easy compliance. But it comes with significant appetite stimulation (which can be counterproductive for body composition goals) and potential impacts on insulin sensitivity and cortisol. The CJC-1295 + ipamorelin combination is more selective: ipamorelin in particular produces clean GH release without affecting cortisol, prolactin, or appetite. The injectable route preserves more natural pulsatile GH patterns. Combined, they produce synergistic GH output greater than either alone. For sleep and recovery optimization, the injectable stack taken before bed is generally preferred. For convenience and accessibility, MK-677 wins. For metabolic health, the injectable stack has a cleaner profile. Many practitioners start patients on MK-677 for convenience, then transition to CJC-1295 + ipamorelin if side effects (appetite, blood sugar) are problematic.
These peptides are often used together. See our stack profiles for combination details.